On 11 June, Chryscapital put down Rs 552 crore to buy Novartis India’s shares held by the public. It ended up spending less than Rs 35,000 for a mere 40 shares.
The private-equity firm’s open offer came after its nearly Rs 1,400 crore deal to buy 70.68% of Novartis India, the listed arm of the Swiss drug major, which it renamed Evonile Pharma. The offer priced the stock at Rs 860.64. A week before it opened, the shares had closed at Rs 1,351. Naturally, almost nobody sold.
About 38,000 public shareholders stayed on, who together own 29% of the company. Chryscapital owns the rest.
Now Evonile wants their money.
On 4 November, Evonile set the terms of a Rs 885-crore rights issue. The price is Rs 860 a share, 64 paise less than Chryscapital offered in June. Most of the money will repay what Evonile borrowed to buy Pfizer’s blood-pressure brand Minipress XL for Rs 1,250 crore.
The strategy is straightforward: buy established brands that multinational drugmakers no longer want to promote, then sell them harder than their previous owners did. The execution, though, is anything but. First, Evonile must compete for these brands with deep-pocketed Indian drugmakers. Then it must sell those brands with a sales force it has only begun building this year, rather than the thousands of medical representatives Indian drugmakers already have on the road.
Can a listed company run by a private-equity firm outbid and outsell India’s established drugmakers? And if it cannot grow fast enough on its own, who will fund the gap?
The market has already placed its bet. Evonile trades at about 60X EV/Ebitda, twice the multiple of a fast-growing domestic drugmaker such as Mankind Pharma. Yet the business it bought has been shrinking, with revenue falling over the last three years.
A rare kind of control
Indian pharma is a founder’s business. After promoters build it, they rarely sell.
Between 2016 and 2025, professional-services firm EY recorded 32 private-equity buyoutsEYPrivate equity buyouts in India in Indian pharma. In contrast, before Evonile, The Ken found only four takeovers in branded medicines in the country.